Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

BioMarin

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of BioMarin's 2012 metabolic sales performance.

Novo Nordisk, bluebird team up to develop haemophilia A therapies

Novo Nordisk, bluebird team up to develop haemophilia A therapies

BioMarin and uniQure are also working on haemophilia A gene therapies.

NICE approves BioMarin’s Brineura after initial setback

NICE approves BioMarin’s Brineura after initial setback However, the therapy has now been approved in the context of a managed access agreement between BioMarin and the cost-effectiveness watchdog. ... However, it is likely that BioMarin will have had to make a concession on price to reach an agreement.

Roche’s Hemlibra scores broader NHS funding

Roche’s Hemlibra scores broader NHS funding BioMarin is in pole position with its candidate valrox, which it plans to submit by the end of 2019.

BioMarin ticks over in Q2 ahead of gene therapy filing

BioMarin ticks over in Q2 ahead of gene therapy filing Jean-Jacques Bienaimé, chief executive officer of BioMarin commented:. Jean-Jacques Bienaimé, CEO, BioMarin. ... BioMarin will also hope to extend the commercial success of Brineura, its Batten disease therapy.

Roche reveals yet another Spark takeover delay

Roche reveals yet another Spark takeover delay Analysts at Jefferies have suggested that is unlikely to be the case, given that a number of other companies are developing haemophilia gene therapies including BioMarin, Sangamo and UniQure which all

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...

Infographics